Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Jazz Pharmaceuticals PLC To Sell Women's Health Business To Meda AB


Thursday, 6 Sep 2012 02:00am EDT 

Jazz Pharmaceuticals PLC announced a definitive agreement to sell women's health business, which includes six products, to Meda AB (an international specialty pharmaceutical company) for $95 million in cash. The products included in the sale are Elestrin (estradiol gel), Gastrocrom(cromolyn sodium, USP), Natelle One (prenatal vitamin), AVC Cream (sulfanilamide), Gesticare DHA (prenatal multi-vitamin) and Urelle (urinary antiseptic). As part of the transaction, Meda will offer positions to approximately 60 Jazz Pharmaceuticals employees who directly support these products. The transaction is expected to close in the fourth quarter of 2012. 

Company Quote

141.38
1.28 +0.91%
30 Jul 2014